Press release: "Antidote Honored to Receive Silver Award From Global Sustainability Authority EcoVadis"

Award recognizes companies that are prioritizing corporate and social responsibility through their operations

New York, NY (July 7, 2022) — Antidote Technologies (“Antidote”), a patient-centric digital engagement company that connects patients with clinical research opportunities, has received a Silver Award from EcoVadis, the world’s only universal sustainability rating provider. 

Antidote was invited to participate in the EcoVadis assessment by one of its major pharmaceutical partners, and was evaluated alongside over 90,000 businesses spanning more than 200 industries in 160+ countries. The Silver Award denotes that Antidote is in the top 25% of companies focusing on Corporate and Social Responsibility in 2022, with criteria considerations including environmental initiatives, human rights practices, sustainability, and corporate ethics. 

“We are honored to have been invited to participate in this assessment and thrilled to receive the Silver Award from EcoVadis,” said Laurent Schockmel, CEO of Antidote. “Our company has been focusing heavily on increasing sustainability and corporate responsibility, and it is gratifying to see our work recognized in such a meaningful way.”

Environmental, Social, and Corporate Governance (ESG) initiatives have been a major priority for Antidote. Through quarterly awareness campaigns, annual volunteer days, and ongoing employee training opportunities, the company is focused on making a positive impact on our communities and our world. This award showcases the impact of the organization’s efforts. 

With over 90% of companies considering sustainability criteria in their purchasing decisions, Antidote is proud to be at the forefront of businesses committed to environmental and social responsibility.1 If you would like to learn more about Antidote’s mission and ESG initiatives, please get in touch.

About Antidote

Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit

About EcoVadis

Founded in 2007, EcoVadis has grown to become the world’s largest and most trusted provider of business sustainability ratings. It has created a global network of more than 90,000 companies, spanning 160+ countries and 200+ industries. Their aim is to make choosing sustainability-focused companies easier for buyers, while making quantifying sustainability efforts a better process for companies.


Media Contacts

Grace McElroy, Antidote 


Lisa Conroy, Antidote